Health

FDA Review of Experimental Melanoma Drug

Updated 2026-07-30 10:10 UTC 1 source Neutral

The FDA is reviewing Replimune’s experimental melanoma drug, RP1, in a live-blogging session. The drug could offer new treatment options for patients with advanced melanoma.

Coverage timeline — 1 article

STAT News

STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment

STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.

2026-07-30 10:00 UTC